Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics plc

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Metric
Company Name	Barinthus Biotherapeutics plc	Sierra Oncology
Symbol	BRNS
MSH ID	COM:BARINTHUSBIO	COM:SIERRAONCOLOGY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	GB	GB
Stage
Employee Count	130
Website	barinthusbio.com	sierraoncology.com
LinkedIn
Founders

Metric
Market Cap	55.90M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	802K
Revenue (LTM)
Revenue (NTM)
Gross Profit	802K
EBITDA	-83.91M
Operating Income	-83.91M
Net Income	-73.35M
EPS	-1.91K
Diluted EPS	-1.91K
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.19
Operating Profit Margin	-10.38
EBITDA Margin	-104.63
Net Profit Margin	-11.91
Return on Equity	-0.35
Return on Assets	-0.34
Return on Capital Employed	-0.33

BRNS

COM:BARINTHUSBIO

Barinthus Biotherapeutics plc

Last Close

0.98

22/11 21:00

Market Cap

55.90M

Beta: -

Volume Today

142.16K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.22
P/B Ratio	0.48
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	116.13
EV Multiple	-2.39

Metric
Days Sales Outstanding	2.23K
Days Payables Outstanding	128.91
Days Inventory Outstanding	0.00
Operating Cycle	2.23K
Cash Conversion Cycle	2.10K
Asset Turnover	0.03

Metric
Operating Cash Flow	-50.92M
Free Cash Flow	-50.92M
Cash Flow to Debt	-3.92
Operating Cash Flow/Sales	-10.17
Free Cash Flow Yield	-0.63

Metric
Cash & Equivalents	142.09M
Accounts Receivable
Inventory
Goodwill	12.21M
Debt to Capitalization	0.07
Debt to Assets	0.06
Current Ratio	12.45
Quick Ratio	11.67

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	6.30
R&D to Revenue	56.05
SG&A to Revenue	49.68